Skip to content

CareDx CDNA Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

GeneDx Holdings logo
GeneDx HoldingsWGS
$38.59M+181%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$37.6M+114%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's cash provided by (used in) financing activity, including discontinued operation?
CareDx (CDNA) reported cash provided by (used in) financing activity, including discontinued operation of -$2.91M in Q1 2026.
How has CareDx's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
CareDx's cash provided by (used in) financing activity, including discontinued operation decreased by 352.7% year-over-year, from -$643K to -$2.91M.
What is the long-term trend for CareDx's cash provided by (used in) financing activity, including discontinued operation?
Over 2 years (2022 to 2025), CareDx's cash provided by (used in) financing activity, including discontinued operation has grown at a 353.8% compound annual growth rate (CAGR), from -$4.54M to -$93.39M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.